BNR (Burning Rock Biotech) Institutional Ownership: 16.22% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNR Burning Rock Biotech Ltd BNR
59 GF Score
Price $9.35
GF Value $7.47
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Institutional Ownership?

Burning Rock Biotech BNR -6.16% 59 Institutional Ownership is 16.22% as of Jul. 21, 2026. GuruFocus rates BNR with a GF Score™ of 59/100 and a GF Value™ of $7.47 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Burning Rock Biotech's institutional ownership is 16.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Burning Rock Biotech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Burning Rock Biotech's Float Percentage Of Total Shares Outstanding is 67.48%.

Burning Rock Biotech Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Burning Rock Biotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burning Rock Biotech Institutional Ownership Chart

Burning Rock Biotech Historical Data

The historical data trend for Burning Rock Biotech can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.03 0.05 0.06 0.48 0.48 0.51 0.56 0.56 0.56 0.53
BNR
59GF Score
Burning Rock Biotech Ltd BNR
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Burning Rock Biotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 16.22% mean?
Burning Rock Biotech (BNR) has a Institutional Ownership of 16.22% as of Jul. 21, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Institutional Ownership too high?
Burning Rock Biotech's current Institutional Ownership is 16.22%. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Institutional Ownership compare to XGN and IDXG?
Burning Rock Biotech's Institutional Ownership of 16.22% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Diagnostics & Research company?
A good Institutional Ownership depends on the Medical Diagnostics & Research industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current Institutional Ownership is 16.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.47, compared to a current price of $9.35 — trading 25.2% above its estimated fair value. The current Institutional Ownership is 16.22%. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current Institutional Ownership is 16.22% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Burning Rock Biotech (BNR) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of $9.35 is trading 25.2% above its estimated GF Value™ of $7.47. GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.

Key valuation signals for BNR:

  • Institutional Ownership: 16.22%
  • GF Value™: $7.47 vs. price of $9.35 (25.2% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges 6BU0:Germany
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score

Get the complete analysis for BNR

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.35
Price
$7.47
GF Value